https://doi.org/10.55788/23987766
“No randomised trials have been performed to compare CS-EMR with conventional EMR for the resection of non-pedunculated lesions without signs of invasiveness,” said Dr Óscar Nogales (Hospital General Universitario Gregorio Marañón, Spain) [1]. Therefore, Dr Nogales and colleagues designed a trial (NCT04418843) to compare the efficacy of both techniques, measured as the absence of recurrence at 6 months. Participants with consecutive non-pedunculate lesions with adenoma or serrated histology with sizes ≥20 mm (n=229) were randomised to CS-EMR or conventional EMR in a 1:1 ratio.
At 6 months, the recurrence rate was significantly higher in participants in the CS-EMR arm than in those who underwent the standard treatment (33.6% vs 16.7%; P=0.007). A subgroup analysis revealed that this effect was particularly present in serrated lesions (34.4% vs 4.2%) and lesions larger than 30 mm (44% vs 19%). “Adverse events were low overall,” added Dr Nogales. No significant differences were found between the 2 arms with respect to delayed bleeding, perforation, post-EMR fever, or post-polypectomy syndrome.
In conclusion, CS-EMR does not appear to be a feasible alternative to conventional EMR in patients with large, non-pedunculate colonic lesions.
- Nogales Ó, et al. Recurrence in large non-pedunculated colonic lesions is significantly higher after cold snare endoscopic mucosal resection than after the standard technique. Results of a randomised controlled trial. LB07, UEG Week 2023, 14–17 October, Copenhagen, Denmark.
Copyright ©2023 Medicom Medical Publishers
Posted on
Previous Article
« How to deal with at-risk patients above the CRC screening age limit? Next Article
Safer removal of large polyps with cold snare technique »
« How to deal with at-risk patients above the CRC screening age limit? Next Article
Safer removal of large polyps with cold snare technique »
Table of Contents: UEGW 2023
Featured articles
SEQUENCE: Risankizumab doubles endoscopic remission rates compared with ustekinumab in CD
What’s New in Artificial Intelligence
Digital intervention relieves symptoms and improves QoL in IBS
GastroGPT: Successful proof-of-concept study of gastroenterology-specific large language model
Other Therapeutics and Outcomes
Primary results from MAESTRO-NASH trial: resmetirom efficacious for NASH
Apraglutide: Advancing the treatment of short bowel syndrome
Endobiliary radiofrequency ablation in pCCA: a pilot study
Raising awareness for microscopic colitis: disease course and predictors
Outcomes of IBD Trials
DIVERSITY1: Filgotinib results in Crohn’s disease leave investigators puzzled
SEQUENCE: Risankizumab doubles endoscopic remission rates compared with ustekinumab in CD
Guselkumab provides benefits in UC regardless of advanced therapy history
INSPIRE: Risankizumab meets all efficacy endpoints in UC
Risankizumab resolves extraintestinal manifestations in CD
Obefazimod takes the spotlight as promising UC treatment
Rapid response to upadacitinib boosts outcomes in severe Crohn’s disease
LUCENT trials: Mirikizumab works in UC, regardless of targeted therapy history
ARTEMIS-UC: New kid in town for UC
Breakthroughs in Colorectal Lesions
Safer removal of large polyps with cold snare technique
Higher recurrence rates with cold snare EMR than with conventional EMR
How to deal with at-risk patients above the CRC screening age limit?
European CRC screening needs to be revised
Advances in Upper Endoscopy and Colonoscopy
Epinephrine boosts efficiency in gastric ESD
Artificial intelligence-aided colonoscopy did not improve outcomes in Lynch syndrome
Can computer technology improve our everyday colonoscopy results?
Is AI-assisted colonoscopy ready for clinical practice?
Should we use E-SEMS or EVT for traumatic oesophageal perforations?
Related Articles
December 7, 2023
Letter from the Editor
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com